|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
From the Institute for Clinical Immunology and
Transfusion Medicine, Justus Liebig University Giessen, Germany; and
The Blood Center of Southeastern Wisconsin, Milwaukee, WI.
Drug-induced immune thrombocytopenia (DITP) is a serious
complication of drug treatment. Previous studies demonstrated that most
drug-dependent antibodies (DDAbs) react with the platelet membrane
glycoprotein (GP) complexes IIb/IIIa and Ib/IX/V. We analyzed the sera
from 5 patients who presented with DITP after intake of carbimazole.
Notably, thrombocytopenia induced by carbimazole was relatively mild in
comparison to patients with DITP induced by quinidine. The sera reacted
with platelets in an immunoassay on addition of the drug. In
immunoprecipitation experiments with biotin-labeled platelets and
endothelial cells, reactivity with the platelet endothelial cell
adhesion molecule-1 (PECAM-1, CD31) could be demonstrated, whereas
neither GPIIb/IIIa nor GPIb/IX was precipitated in the presence of the
drug. These results could be confirmed by GP-specific immunoassay
(MAIPA) using monoclonal antibodies (mabs) against PECAM-1. In
addition, the binding of DDAbs could be abolished by preincubation with
soluble recombinant PECAM-1. Carbimazole-dependent antibodies showed
similar reactivity with platelets carrying the Leu125 and
Val125 PECAM-1 isoforms, indicating that this polymorphic
structure, which is located in the first extracellular domain, is not
responsible for the epitope formation. Binding studies with
biotin-labeled mutants of PECAM-1 and analysis of sera with mabs
against different epitopes on PECAM-1 in MAIPA assay suggested that
carbimazole-dependent antibodies prominently bound to the second
immunoglobulin homology domain of the molecule. Analysis of 20 sera
from patients with quinidine-induced thrombocytopenia by MAIPA assay
revealed evidence that DDAbs against PECAM-1 are involved in addition
to anti-GPIb/IX and anti-GPIIb/IIIa. We conclude that PECAM-1 is an
important target GP in DITP.
(Blood. 2000;96:1409-1414) Drug-induced immune thrombocytopenia (DITP) is a
serious side effect of pharmaceutical treatment that has been
attributed to many drugs.1 However, confirmation of the
responsible drug-dependent antibodies (DDAbs) was successful only for
certain selected substances. DDAbs against quinine/quinidine,
sulfonamide antibiotics, and ranitidine are relatively frequent and
have, therefore, been well characterized.2-4 In some
instances, not only the drug itself but also its metabolites are
responsible for the immune response in the patient.5 DDAbs
bind to platelets via their Fab fragments and usually recognize
epitopes on the glycoprotein (GP) complexes Ib/IX and/or IIb/IIIa
( Carbimazole (1-carbethoxy-3-methyl-2-thioimidazole) is a
thioamide that is used for the treatment of hyperthyroidism
(not available in the United States). Hemocytopenias caused by this drug are regarded as rare events and are usually attributed to bone
marrow suppression.18 Carbimazole has been implicated in drug-induced immune hemolytic anemia, but so far immune
thrombocytopenia caused by this drug has not been
observed.19
In this study, we identified DDAbs against PECAM-1 in the sera from 5 patients with drug-dependent thrombocytopenia resulting from treatment
with carbimazole. Furthermore, we have characterized the target
molecules in quinidine-induced immune thrombocytopenia.
Case reports
Patient 2, an 83-year-old woman, was treated with carbimazole
for Graves disease for several years. She was admitted to the hospital
with fever and clinical signs of pneumonia. Mild thrombocytopenia (140 × 109/L) led to suspicion of DITP. Therefore, carbimazole
was replaced by propylthiouracil, and the platelet count recovered
to 340 × 109/L.
Patient 3, a 69-year-old woman, had hyperthyreosis for about 1 year before she was admitted to the hospital with dizziness, tremor,
tachycardia, and dyspnea. Laboratory examination revealed the typical
findings of hyperthyroidism. The patient was treated with carbimazole.
Mild thrombocytopenia with a platelet count of 60 × 109/L
was found. The low platelet counts could be traced back to the
beginning of drug therapy. No immunological signs of autoimmune thrombocytopenia were found by direct monoclonal antibody-specific immobilization of platelet antigen (MAIPA) assay. The bone marrow showed an increased number of megakaryocytes. Carbimazole was stopped.
Thyroidectomy was performed after the patient had developed severe
hyperthyroidism. Subsequently the platelet count normalized to
194 × 109/L.
Patient 4 was a 78-year-old woman with B-cell lymphoma who
suffered from hyperthyroidism for several years. On hospitalization, she received carbimazole and heparin besides other drugs. A drop in the
platelet count from 228 × 109/L to 112 × 109/L was initially attributed to heparin-induced
thrombocytopenia. However, different methods for the detection of
antibodies of heparin-induced thrombocytopenia revealed negative
results. The bone marrow showed normal numbers of megakaryocytes.
Patient 5 was a 60-year-old woman who received carbimazole for
hyperthyroidism with focal adenoma for several years. Over a period of
1 year, her platelet count diminished from normal values to 124 × 109/L and further to 40 × 109/L. Autoimmune
thrombocytopenia was discussed, but, after careful examination, DITP
was suspected.
Patients with antibodies against quinidine. Sera from 20 patients who experienced acute thrombocytopenia after the intake of
quinidine were analyzed. All sera showed positive reactions in a
binding assay on addition of quinidine. From 18 patients, 10 were male
and 8 were female. Their mean age was 65.5 years (24-85 years,
n = 17). From 15 patients, clinical data could be evaluated. All of
them showed a hemorrhagic diathesis with acute onset of the
following symptoms: petechiae (15), hematoma (6), mucosal
bleeding/epistaxis (6), melena (2), and hematuria (1). The nadir of
platelet counts was between 1 × 109/L and 25 × 109/L (median 7.5 × 10/9/L). Thrombocytopenia
resolved after interruption of quinidine intake.
Monoclonal antibodies
Mabs Gi18 and Gi34 specific for immunoglobulin homology loops 1-2 and loops 2-3 of PECAM-1, respectively, were produced in our laboratory.21,22 CD31-specific mabs PECAM-1.2 and -1.3 directed against loop 6 and loops 1-2, respectively, were kindly provided by Dr P. Newman (Milwaukee, WI).21 Enzyme immunoassay Platelets (2 × 107) were incubated with 20 µL serum and 30 µL of the respective drug (1 mg/mL) for 30 minutes at 37°C, washed three times with isotonic saline-containing drug (0.1 mg/mL), and then incubated with alkaline phosphatase-conjugated goat anti-human immunoglobulin G (IgG; dilution 1:25 000; Dianova, Hamburg, Germany) in the presence of drug (0.1 mg/mL). After washings, the binding of antibody was visualized with p-nitrophenylphosphate as substrate (Sigma).Flow cytometry analysis Paraformaldehyde-fixed platelets (108) were incubated with 20 µL human serum in the absence or in the presence of 10 µL drug (1 mg/mL) for 30 minutes at room temperature. Platelets were then washed twice with phosphate-buffered saline (PBS), stained with 40 µL fluorescein-isothiocyanate-conjugated (FITC) rabbit anti-human IgG (dilution 1:40; DAKO, Hamburg, Germany) for 30 minutes at room temperature. After washing three times, platelets were analyzed by flow cytometry (Ortho Diagnostic, Neckargemuend, Germany). In some instances, serum was preincubated with 1 µL recombinant-soluble PECAM-1 (r-PECAM-1; 640 ng/µL) in the presence of carbimazole for 30 minutes at room temperature prior to flow cytometry analysis.MAIPA assay Antibody screening was performed by using the MAIPA assay as previously described.23,24 For the analysis of DDAbs, 2 × 107 platelets or 1 × 106 human umbilical vein endothelial cells were incubated with 20 µL serum, 10 µL mab (20 µg/mL), and 30 µL of the respective drug (1 mg/mL). Bound IgG was detected by using horseradish peroxidase anti-human IgG (dilution 1:3,000; Dianova) and o-phenylenediamine substrate (Sigma). All buffers contained 0.1 mg/mL of the respective drug.Immunoprecipitation Platelets derived from a blood group O donor, human umbilical vein endothelial cells, or L-cells expressing PECAM-1 mutants were surface labeled with 5 mmol/L NHS-LC-Biotin (Paesel, Frankfurt, Germany) as previously described.20 Aliquots of 100 µL precleared lysates were incubated overnight at 4°C with 100 µL purified mabs (1 µg) or 50 µL serum in the absence or in the presence of 50 µL carbimazole (1 mg/mL). In some instances, serum was preincubated with 1 µL r-PECAM-1 (see above) in the presence of carbimazole for 30 minutes at room temperature prior to immunoprecipitation. Precipitates were electrophoresed on 7.5% SDS polyacrylamide gel, blotted, and visualized using streptavidin-horseradish peroxidase and chemiluminescence substrate (ECL; Amersham Buchler, Braunschweig, Germany).Genotyping of C  G dimorphism was performed as previously
described with minor modification.14 In brief, 5 µL
genomic DNA was added to a 50 µL reaction mixture containing 10 mmol/L Tris (pH 8.0); 50 mmol/L KCl; 2.75 mmol/L MgCl2;
0.125 mmol/L of each dNTP; 0.25 µmol/L each sense primer
5'-CTGCCTTCCTTCGGGTTGCA-3' and sequence-specific antisense primer
5'-CAAGGACTCACCTTCCACCAACAG-3' or 5'-CAAGGACTCACCTTCCACCAACAC-3'; and
2.5 units TaqGold (Perkin Elmer). After initial denaturation at 96°C
for 10 minutes, amplification was performed in a DNA thermocycler
(Perkin Elmer) for 5 cycles (denaturation at 94°C for 1 minute,
annealing at 63°C for 30 seconds, and extension at 72°C for 30 seconds) and 30 cycles of denaturation at 94°C for 1 minute,
annealing at 61°C for 30 seconds, and extension at 72°C for 30 seconds. The PCR products were analyzed by electrophoresis on 1.8%
agarose gels by using Tris-borate/EDTA buffer by ethidium bromide
staining. DNA molecular marker V was used as standard (Boehringer Mannheim).
Characterization of carbimazole-dependent antibodies Sera from 5 patients with clinically suspected DITP induced by carbimazole were analyzed in enzyme immunoassay (Figure 1). All sera showed a typical reaction pattern with significant binding of antibodies in the presence of 1 mg/mL drug. No binding of IgG occurred without carbimazole. The ratios (optical density with drug/optical density without drug) ranged from 5.9 to 41. To localize the target glycoprotein of carbimazole-dependent antibodies, the MAIPA assay was performed with a panel of mabs. As shown in Figure 2, strong carbimazole-dependent antibody binding was detected when mabs against PECAM-1 (Gi18, Gi34, PECAM-1.2, and PECAM-1.3) were used as capture antibodies and only in the presence of carbimazole. The ratios of optical densities ranged from 24.8 to 200. In contrast, no reactivity was observed with GPIb/IX and GPIIb/IIIa immobilized by mabs FMC25 and Gi5, respectively (data not shown). The reactivity of DDAbs with PECAM-1 was strongest when a capture antibody against domain 6 (PECAM-1.2) was used. In contrast, weaker reactions were observed with mabs against loops 1, 2, and 3. The weakest reaction was detected with mab PECAM-1.3 directed against loops 1-2 (Figure 2). These findings indicated an inhibition of the binding of DDAbs by mabs that recognize epitopes residing on distal loops of this molecule. In flow cytometry, the patient's sera reacted with normal platelets in the presence but not in the absence of carbimazole. Figure 3 shows a representative experiment with serum from patient 2. If the serum was preincubated with r-PECAM-1, the reactivity could be abolished, demonstrating that the DDAbs bound exclusively to PECAM-1 but not to other platelet membrane constituents. These results could be confirmed by immunoprecipitation analysis with biotin-labeled platelets (Figure 4A). Carbimazole-dependent antibodies precipitated solely PECAM-1 with an apparent molecular weight (Mr) of 130 kd under nonreducing conditions. In control experiments with mab Gi18, a protein with the same Mr was precipitated. In addition, the carbimazole-dependent antibodies failed to precipitate any platelet protein when r-PECAM-1 was added. Altogether, these data demonstrated that sera from patients with carbimazole-induced thrombocytopenia contained antibodies that drug-dependently bound to PECAM-1.
Reactivity of carbimazole-dependent antibodies with endothelial cells Because endothelial cells express considerable amounts of PECAM-1, the reactivity of carbimazole-dependent antibodies with these cells should be assessed. In immunoprecipitation with biotin-labeled human umbilical vein endothelial cells, PECAM-1 was precipitated in the presence of the drug in parallel as from platelets (Figure 4). No other endothelial cell protein could be precipitated. On analysis in MAIPA assay, carbimazole-dependent antibodies reacted with PECAM-1 derived from endothelial cells (Figure 5). Furthermore, when the serum was pre-absorbed twice with endothelial cells or platelets (as control), the reactivity with PECAM-1 was abolished. Therefore, carbimazole-dependent antibodies recognize PECAM-1 derived both from platelets and from endothelial cells.
Reactivity of carbimazole-dependent antibodies with PECAM-1 (Leu/Val125) isoforms Recently, it was demonstrated that the Leu125 and Val125 isoforms of PECAM-1 showed different reactivity with mab 7E8.14 Therefore, we sought to determine if the reactivity of carbimazole-dependent antibodies against PECAM-1 differs between different individuals because of differences of the two isoforms. Ten normal blood donors were typed for the dimorphism by allele-specific PCR. In positive individuals, a 342 base pair (bp) PCR product was amplified. Three donors were CC homozygous (Leu125), 1 donor had a GG genotype (Val125), and 6 individuals were typed CG heterozygous. Platelets of a Leu125 and a Val125 homozygous donor, respectively, were assessed with carbimazole-dependent antibodies by flow cytometry. Figure 6 demonstrates that no differences in the binding of the antibodies could be observed between the two PECAM-1 isoforms.
Reactivity of carbimazole-dependent antibodies with PECAM-1 mutants To substantiate the finding of predominant binding to distal extracellular domains of PECAM-1, serum containing carbimazole-dependent antibodies (patient 2) was tested with lysates from biotin-labeled L-cells transfected with PECAM-1 mutants. As shown in Figure 7, the serum reacted with the wild type of PECAM-1 and with a mutant in which the first extracellular domain was deleted ( 1). In contrast, mutants lacking
the second extracellular domain (2) failed to react with
carbimazole-dependent antibodies (Figure 7A, lane 4). In the control
experiment, mab PECAM-1.2 directed against extracellular loop 6 reacted
with wild-type, 1, and 2 mutants. These findings suggested that
the second extracellular loop contributes primarily to the epitope
formation for carbimazole-dependent antibodies.
Analysis of quinidine-dependent antibodies by MAIPA assay We analyzed sera from 20 patients with quinidine-induced thrombocytopenia in enzyme immunoassay and in MAIPA assay. In enzyme immunoassay, quinidine-dependent antibodies were detected in all 20 sera. Subsequently, sera were analyzed in MAIPA assay for their reactivity with PECAM-1, GPIb/IX, GPIIb/IIIa, and GPIa/IIa by using mabs Gi18, FMC25, Gi5, and Gi9, respectively. A positive reaction was defined as an optical density above 0.100. Results with GPIb/IX, GPIIb/IIIa, and PECAM-1 are given in Table 1. Most quinidine-dependent antibodies reacted strongly with GPIb/IX and/or GPIIb/IIIa. In contrast, only moderate reactivity was observed with PECAM-1. No drug-dependent antibody reactivity directed against GPIa/IIa was observed in any of the sera tested. To exclude coprecipitation of PECAM-1 with other platelet GPs under MAIPA conditions, a representative panel of autoantibodies against GPIIb/IIIa and/or GPIb/IX and anti-GPIa/IIa alloantibody (anti-Bra) were analyzed in the presence and in the absence of quinidine. No co-reactivity with PECAM-1 was detectable (Table 1). In addition, the presence of quinidine did not alter the reactivity of autoantibodies or alloantibodies to their respective target GPs.
In this study, we report on 5 patients with drug-dependent platelet reactive antibodies against carbimazole. The sera showed a strong reactivity with PECAM-1 in a GP-specific immunoassay (MAIPA) when mabs against PECAM-1 were used for antigen immobilization (Figure 2). The specificity for this target could be confirmed by immunoprecipitation experiments (Figure 4). In addition, the reactivity of DDAbs was abolished in the presence of r-PECAM-1 by flow cytometry as well as by immunoprecipitation (Figures 3 and 4). These results strongly indicate that PECAM-1 was the only molecule on platelets that is recognized by the antibodies. Furthermore, we could demonstrate by immunoprecipitation and by MAIPA assay that carbimazole-dependent antibodies were also reactive with PECAM-1 from endothelial cells (Figures 4 and 5). Other DDAbs (eg, in response to quinine/quinidine) mostly recognize GPIb/IX and/or GPIIb/IIIa as targets.7-9 The isolated involvement of PECAM-1 in carbimazole-dependent thrombocytopenia without additional DDAbs against the other two GP complexes may be due to a specific interaction between the drug and PECAM-1. However, no tight binding of the drug to the platelet membrane that resisted washing procedures without the drug was observed (data not shown). Several attempts have been made to localize the binding domains of DDAbs on their target GPs.2,9 By the use of a panel of mabs against different epitopes on the extracellular domain of PECAM-1 in MAIPA assay, we observed an inhibition with mabs against the distal loops 1, 2, and 3 (PECAM-1.3, Gi18, and Gi34) but not with mab PECAM-1.2 that binds to the most proximal loop 6 (Figure 2). This observation led us to the assumption that binding occurred in the distal domains. To further localize the binding domain of drug-dependent antibody, immunoprecipitation with various PECAM-1 mutants was performed. Deletion of the second extracellular domain from PECAM-1 abolished the binding of the antibody, whereas, on deletion of the first domain, PECAM-1 was still recognized (Figure 7). These findings indicate that the second extracellular domain is critical for antibody binding. In comparison, DDAbs that occur in response to other drugs as well as autoantibodies predominantly recognized membrane-associated regions of the respective GP complex.2,4,8,25 However, quinidine-dependent antibodies against the distal glycocalicin region of GPIb have also been observed.2 Recently, the presence of a C The finding of PECAM-1 as the only target of DDAbs in carbimazole-induced thrombocytopenia led us to the analysis of sera from patients with quinidine-dependent thrombocytopenia. As expected, we found strong reactions with GPIb/IX and GPIIb/IIIa and thereby confirmed the previous findings that these two GPs comprise the target antigens in quinidine-induced thrombocytopenia.2,7-9 On analysis in the MAIPA assay, we found additional reactivity of several sera with PECAM-1 that was only detectable in the presence of drug. Interestingly, the reaction with PECAM-1 was only observed when additional reactivity against GPIb/IX and/or GPIIb/IIIa was detectable. One may speculate that unspecific interaction between PECAM-1 and other membrane constituents on the platelet membrane contribute to the reactivity of quinidine-dependent antibodies in GP-specific immunoassays. However, no reactions were observed with GPIa/IIa in this assay among all serum samples. In addition, negative results were obtained with anti-PECAM-1 mab when autoantibodies or alloantibodies were analyzed against GPIIb/IIIa, GPIb/IX, or GPIa/IIa. Our patients with quinidine-dependent antibodies presented with the typical clinical finding of pronounced hemorrhagic diathesis and severe acute thrombocytopenia. In comparison, the patients with carbimazole-dependent antibodies had only mild thrombocytopenia, which in some instances was only relative to platelet counts before or after the intake of the drug. Because severe thrombocytopenia is usually expected in DITP, platelet reactive antibodies against carbimazole might have been overlooked in the past. Relative thrombocytopenia with a decrease in platelet counts of about 50% is a well-known phenomenon in heparin-induced thrombocytopenia.26 It is, therefore, not surprising that, in 2 of our patients with carbimazole-induced antibodies, heparin-induced thrombocytopenia was suspected initially. Another reason not to suspect DDAbs in patients receiving carbimazole is the attribution of thrombocytopenia to underlying Graves disease. The association of hyperthyroidism with secondary autoimmune thrombocytopenia has been observed on several occasions.27,28 One may speculate that mild thrombocytopenia in our patients with carbimazole-dependent antibodies was related to the exclusive reactivity of the antibodies with PECAM-1, a target molecule that is present in large amounts on endothelial cells and certain blood cells (eg, granulocytes).29 Absorption of the antibody could occur on PECAM-1-expressing cells and could, therefore, have reduced the clearance of platelets, resulting in mild thrombocytopenia. We conclude that PECAM-1 has to be added to the list of target GPs in DITP. It may be involved as a sole target molecule in carbimazole-dependent antibodies, but it may also be an additional target for antibodies resulting from treatment with other drugs such as quinidine. Further studies will be required to analyze the possible role of PECAM-1 in DITP resulting from treatment with other drugs.
We appreciate the excellent technical assistance of Ms Astrid Giptner and Ms Monika Kuemmel. We express our gratitude to the physicians who cared for the patients in this study, for contribution of detailed clinical observations.
Submitted December 6, 1999; accepted March 28, 2000.
Supported by grant DFG Sa 480/2-1 from the German Research Foundation.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Hartmut Kroll, Institute for Clinical Immunology and Transfusion Medicine, Justus Liebig University, Langhansstr. 7, D-35392 Giessen, Germany; e-mail: hartmut.e.kroll{at}immunologie.med.uni-giessen.de.
1. Aster RH. Drug-induced thrombocytopenia: an overview of pathogenesis. Sem Hematol. 1999;36:2-6[Medline] [Order article via Infotrieve].
2.
Chong BH, Du X, Berndt MC, Horn S, Chesterman CN.
Characterization of the binding domains on platelet glycoproteins Ib-IX and IIb/IIIa complexes for the quinine/quinidine-dependent antibodies.
Blood.
1991;77:2190-2199
3.
Curtis BR, McFarland JG, Wu GG, Visentin GP, Aster RH.
Antibodies in sulfonamide-induced immune thrombocytopenia recognize calcium-dependent epitopes on the glycoprotein IIb/IIIa complex.
Blood.
1994;84:176-183
4.
Gentilini G, Curtis BR, Aster RH.
An antibody from a patient with ranitidine-induced thrombocytopenia recognizes a site on glycoprotein IX that is a favored target for drug-induced antibodies.
Blood.
1998;92:2359-2365 5. Kiefel V, Santoso S, Schmidt S, Salama A, Mueller-Eckhardt C. Metabolite-specific (IgG) and drug-specific antibodies (IgG, IgM) in two cases of trimethoprime-sulfamethoxazole-induced immune thrombocytopenia. Transfusion. 1987;27:262-265[Medline] [Order article via Infotrieve]. 6. Christie DJ, Mullen PC, Aster RH. Fab-mediated binding of drug-dependent antibodies to platelets in quinidine- and quinine-induced thrombocytopenia. J Clin Invest. 1985;75:310-314.
7.
Berndt MC, Chong BH, Bull HA, Zola H, Castaldi PA.
Molecular characterization of quinine/quinidine drug-dependent antibody platelet interaction using monoclonal antibodies.
Blood.
1985;66:1292-1301
8.
Visentin GP, Newman PJ, Aster RH.
Characteristics of quinine- and quinidine-induced antibodies specific for platelet glycoproteins IIb and IIIa.
Blood.
1991;77:2668-2676
9.
Burgess JK, Lopez JA, Berndt MC, Dawes I, Chesterman CN, Chong BH.
Quinine-dependent antibodies bind a restricted set of epitopes on the glycoprotein Ib-IX complex: characterization of the epitopes.
Blood.
1998;92:2366-2373 10. Santoso S, Kiefel V, Mueller-Eckhardt C. Blood group A and B determinants are expressed on platelet glycoproteins IIa, IIIa, and Ib. Thromb Haemost. 1991;65:196-201[Medline] [Order article via Infotrieve]. 11. Santoso S, Mueller-Eckhardt C. PECAM is the major glycoprotein on platelets carrying blood group antigens [abstract]. Thromb Haemost. 1993;69:1191.
12.
Newman PJ, Berndt MC, Gorski J, et al.
PECAM-1 (CD31) cloning and relation to adhesion molecules of the immunoglobulin gene superfamily.
Science.
1990;247:1219-1222 13. Newman PJ. The biology of PECAM-1. J Clin Invest. 1997;99:3-8[Medline] [Order article via Infotrieve].
14.
Behar E, Chao NJ, Hiraki DD, et al.
Polymorphism of adhesion molecule CD31 and its role in acute graft-versus-host disease.
N Engl J Med.
1996;334:286-291 15. Balduini CL, Noris P, Giorgiani G, et al. Incompatibility for CD31 and human platelet antigens and acute graft-versus-host disease after bone marrow transplantation. Br J Haematol. 1999;106:723-729[Medline] [Order article via Infotrieve].
16.
Nichols WC, Antin JH, Lunetta KL, et al.
Polymorphism of adhesion molecule CD31 is not a significant risk factor for graft-versus-host disease.
Blood.
1996;88:4429-4434 17. Da Costa L, Charron D, Loiseau P. Does the adhesion molecule CD31 act as a minor histocompatibility antigen? Blood. 1997;90:1332-1332[Medline] [Order article via Infotrieve]. 18. Bartalena L, Bogazzoi F, Martino E. Adverse effects of thyroid hormone preparations and antithyroid drugs. Drug Safety. 1996;15:53-63[Medline] [Order article via Infotrieve]. 19. Salama A, Northoff H, Burkhardt H, Mueller-Eckhardt C. Carbimazole-induced immune haemolytic anaemia: role of drug-red blood cell complexes for immunization. Br J Haematol. 1988;68:479-482[Medline] [Order article via Infotrieve].
20.
Santoso S, Kalb R, Kiefel V, Mueller-Eckhardt C, Newman PJ.
The human platelet alloantigens Bra and Brb are associated with a single amino acid polymorphism on glycoprotein Ia (integrin 21. Yan HC, Newman PJ, Albelda SM. Epitope mapping of CD31 (PECAM-1) mAb. In: Schlossman SF,Boumsell L,Gilks W,et al., eds. Leucocyte Typing V: White Cell Differentiation Antigens: Proceedings of the Fifth International Workshop and Conference Held in Boston, USA, 3-7 November 1993. Oxford: Oxford University Press; 1995:1261-1262. 22. Sun QH, DeLisser HM, Paddock C, Liu CY, Albelda SM, Newman PJ. CD31 workshop: epitope mapping of CD31 monoclonal antibodies and a study of their effects on PECAM-1 homophilic interaction. In: Kishimoto T,Kikutani H,von dem Borne AE,et al., eds. Leukocyte Typing VI: White Cell Differentiation Antigens: Proceedings of the Sixth International Workshop and Conference Held in Kobe, Japan, 10-12 November 1996. New York: Garland Publishing; 1998:367-368.
23.
Kiefel V, Santoso S, Weisheit M, Mueller-Eckhardt C.
Monoclonal antibody-specific immobilization of platelet antigens (MAIPA): a new tool for the identification of platelet-reactive antibodies.
Blood.
1987;70:1722-1726 24. Kiefel V. The MAIPA assay and its applications in immunohaematology. Transfus Med. 1992;2:181-188[Medline] [Order article via Infotrieve]. 25. Kekomäki R, Dawson B, McFarland JG, Kunicki TJ. Localization of human platelet autoantigens to the cystein-rich region of glycoprotein IIIa. J Clin Invest. 1991;88:847-854. 26. Warkentin TE. Heparin-induced thrombocytopenia: a clinicopathological syndrome. Thromb Haemost. 1999;82:439-447[Medline] [Order article via Infotrieve].
27.
Hofbauer LC, Spitzweg C, Schmauss S, Heufelder AE.
Graves disease associated with autoimmune thrombocytopenic purpura.
Arch Intern Med.
1997;157:1033-1036 28. Ma MX, Yu JR, Cai ZQ. Clinical analysis of 36 cases of coexistent hyperthyroidism with idiopathic thrombocytopenic purpura. Chung Hua Nei Ko Tsa Chih. 1989;28:136-138. 29. Bux J, Ernst-Schlegel M, Rothe B, Panzer C. Neutropenia and anaemia due to carbimazole-dependent antibodies. Br J Haematol. In press.
© 2000 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  U. J. H. Sachs, C. L. Andrei-Selmer, A. Maniar, T. Weiss, C. Paddock, V. V. Orlova, E. Y. Choi, P. J. Newman, K. T. Preissner, T. Chavakis, et al. The Neutrophil-specific Antigen CD177 Is a Counter-receptor for Platelet Endothelial Cell Adhesion Molecule-1 (CD31) J. Biol. Chem., August 10, 2007; 282(32): 23603 - 23612. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Chavakis, T. Keiper, R. Matz-Westphal, K. Hersemeyer, U. J. Sachs, P. P. Nawroth, K. T. Preissner, and S. Santoso The Junctional Adhesion Molecule-C Promotes Neutrophil Transendothelial Migration in Vitro and in Vivo J. Biol. Chem., December 31, 2004; 279(53): 55602 - 55608. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Asvadi, Z. Ahmadi, and B. H. Chong Drug-induced thrombocytopenia: localization of the binding site of GPIX-specific quinine-dependent antibodies Blood, September 1, 2003; 102(5): 1670 - 1677. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Kroll, A. Giptner, and S. Santoso Drug-dependent antibodies against the prodrug carbimazole do not react with the active metabolite thiamazole Blood, April 1, 2001; 97(7): 2186 - 2187. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2000 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
IIb
3-integrin).
